AVN-101, a close structural analogue of latrepirdine, is a selective 5-HT6 receptor antagonist which is under development by Avineuro Pharmaceuticals for the treatment of Alzheimer's disease and anxiety disorders.[1][2][3] As of November 2013, it was in phase II clinical trials for these indications.[2][3][4][needs update]
Identifiers | |
---|---|
| |
CAS Number |
|
ChemSpider |
|
UNII |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C21H24N2 |
Molar mass | 304.437 g·mol−1 |
3D model (JSmol) |
|
| |
|
It was approved in Russia on May 31, 2023 under the brand name Aviandr for the treatment of generalized anxiety disorder, mild-to-moderate anxiety conditions (stress reactions and adjustment disorders) and anxiety after COVID-19.[5]